Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does individual response to androgen replacement therapy affect bone density?

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Meier C et al. (2005) Endocrine regulation of bone turnover in men. Clin Endocrinol (Oxf) 63: 603–616

    CAS  Google Scholar 

  2. Behre HM et al. (1999) Long-term substitution therapy of hypogonadal men with trans-scrotal testosterone over 7-10 years. Clin Endocrinol (Oxf) 50: 629–635

    CAS  Google Scholar 

  3. Wang C et al. (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89: 2085–2098

    CAS  Google Scholar 

  4. Zitzmann M et al. (2004) X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J Clin Endocrinol Metab 89: 6208–6217

    CAS  PubMed  Google Scholar 

  5. Liu PY et al. (2004) The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 89: 4789–4796

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Ian Newman, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ronald S Swerdloff.

Ethics declarations

Competing interests

Ronald S Swerdloff and Christina Wang have received grants from Besins/Ascend, Clarus, Columbia, MacroChem Corporation, Organon, Schering AG, and Solvay Pharmaceuticals, Inc.; they have acted as Consultants for Auxillium, Besins/Ascend, Clarus, Columbia, MacroChem Corporation, Organon, Pierre Fabre, Schering AG, Solvay Pharmaceuticals, Inc. and Zonagen, and have had talks sponsored by Auxillium, Adventa, Schering AG and Solvay Pharmaceuticals, Inc. Neither Dr Swerdloff nor Dr Wang is a shareholder or owner of any of these companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, P., Wang, C. & Swerdloff, R. Does individual response to androgen replacement therapy affect bone density?. Nat Rev Endocrinol 2, 76–77 (2006). https://doi.org/10.1038/ncpendmet0094

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0094

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing